Coramaze Technologies develops the Tripair, a simple, rapid, and effective percutaneous treatment for tricuspid valve disease. The treatment is intended to improve quality of life and reduce morbidity for heart failure patients suffering from tricuspid regurgitation. The Tripair implant is anchored a-traumatically in the right atrium, enabling full retrievability and intraprocedural efficacy evaluation while reducing regurgitation even in the most severe cases.